Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Employers are projecting a median 10% increase in healthcare costs for 2026, driven largely by high claims and specialty drug ...

The Trump administration is directing the Department of Health and Human Services to identify about 26 “critical medicines.” ...

Hospital margins improved in June as revenue gains outpaced patient volume — but Kaufman Hall’s latest data shows that financial gaps between high- and low-performing organizations persist, with ...

Even with venture capital fundraising slowing down, Hatteras Venture Partners was able to close two new funds for investments in seed- and early-stage companies. We also have a recap of recent ...

Pfizer’s inclacumab did not beat a placebo in a Phase 3 test in sickle cell disease. The trial failure comes nearly a year after Pfizer voluntarily withdrew Oxbryta from the market after tests ...

Noom recently launched a microdosing program for GLP-1s. However, some are concerned about the use of compounded GLP-1s in this program, as they are not FDA-approved.

Isaac Health, a startup specializing in cognitive care for Alzheimer’s dementia , raised $10.5 million in Series A funding to expand nationwide access to its platform. The company partners with ...

Some large health systems are experimenting with selling their internal capabilities — such as IT support, revenue cycle management and call center operations — to smaller hospitals as a new ...

To prevent further harm and ensure families aren’t left behind again, we must use data more proactively — not only to close gaps in coverage but also to support accountability in how care ...